Skip to main content
SpringerLink
Log in

Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Individuals with Down syndrome (DS) are at high risk for developing Alzheimer’s disease (AD) pathology and this has provided significant insights into our understanding of the genetic basis of AD. The present review summarizes recent clinical, neuropathologic, imaging, and fluid biomarker studies of AD in DS (DSAD), highlighting the striking similarities, as well as some notable differences, between DSAD and the more common late-onset form of AD (LOAD) in the general population, as well as the much rarer, autosomal-dominant form of AD (ADAD). There has been significant progress in our understanding of the natural history of AD biomarkers in DS and their relationship to clinically meaningful changes. Additional work is needed to clearly define the continuum of AD that has been described in the general population, such as the preclinical, prodromal, and dementia stages of AD. Multiple therapeutic approaches, including those targeting not only β-amyloid but also tau and the amyloid precursor protein itself, require consideration. Recent developments in the field are presented within the context of such efforts to conduct clinical trials to treat and potentially prevent AD in DS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Down JLH. Observations on an ethnic classification of idiots. Lond Hosp Clin Lect Rep. 1866;3:259–62.

    Google Scholar 

  2. Lejeune J, Gautier M, Turpin R. A study of somatic chromosomes in nine infants with mongolism. CR Acad Sci (Paris). 1959;240:1026–7.

    Google Scholar 

  3. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987;235:880–4.

    CAS  Google Scholar 

  4. Murrell J, Farlow M, Ghetti B, et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science. 1991;254:97–9.

    CAS  PubMed  Google Scholar 

  5. Goate A, Chartier-Hardin M-C, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704–76.

    CAS  PubMed  Google Scholar 

  6. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359(9311):1019–25.

    PubMed  Google Scholar 

  7. Rubenstein E, Hartley S, Bishop L. Epidemiology of Dementia and Alzheimer Disease in Individuals with Down Syndrome. JAMA Neurol. 2020;77(2):262–4.

    Google Scholar 

  8. McCarron M, McCallion P, Reilly E, et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2017;61:843–52.

    CAS  PubMed  Google Scholar 

  9. Hithersay R, Startin CM, Hamburg S, et al. Association of dementia with mortality among adults with down syndrome older than 35 years. JAMA Neurol. 2019;76(2):152–60.

    PubMed  Google Scholar 

  10. Bayen E, Possin KL, Chen Y, et al. Prevalence of aging, dementia, and multimorbidity in older adults with down syndrome. JAMA Neurol. 2018;75(11):1399–406.

    PubMed  PubMed Central  Google Scholar 

  11. Landes SD, Stevens JD, Turk MA. Obscuring effect of coding developmental disability as the underlying cause of death on mortality trends for adults with developmental disability: a cross-sectional study using US Mortality Data from 2012 to 2016. BMJ Open. 2019;9(2):e026614.

    PubMed  PubMed Central  Google Scholar 

  12. Antonarakis SE. Human chromosome 21: genome mapping and exploration circa 1993. Trends Genet. 1993;9:142–8.

    CAS  PubMed  Google Scholar 

  13. Thuline HC, Pueschel SM. Cytogenetics in Down syndrome. In: Pueschel SM, Rynders JE, editors. Down syndrome. Advances in biomedicine and the behavioral sciences. Cambridge: Ware Press; 1982. p. 133.

    Google Scholar 

  14. Asim A, Kumar A, Muthuswamy S, et al. Down syndrome: an insight of the disease. J Biomed Sci. 2015;22(1):41.

    PubMed  PubMed Central  Google Scholar 

  15. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977–83.

    PubMed  Google Scholar 

  16. McNaughton D, Knight W, Guerreiro R, et al. Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol Aging. 2012;33:426.e13–21.

    CAS  Google Scholar 

  17. Rumble B, Retallack R, Hilbich C, et al. Amyloid A4 and its precursor in Down’s syndrome and Alzheimer’s disease. N Engl J Med. 1989;320:1446–62.

    CAS  PubMed  Google Scholar 

  18. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24–6.

    CAS  PubMed  Google Scholar 

  19. Cabrejo L, Guyant-Maréchal L, Laquerrière A, et al. Phenotype associated with APP duplication in five families. Brain. 2006;129:2966–76.

    PubMed  Google Scholar 

  20. Wallon D, Rousseau S, Rovelet-Lecrux A, et al. The French series of autosomal dominant early onset Alzheimer’s disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2012;30:847–56.

    CAS  PubMed  Google Scholar 

  21. Carmona-Iragui M, Balasa M, Benejam B, et al. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer’s disease. Alzheimers Dement. 2017;13:1251–60.

    PubMed  PubMed Central  Google Scholar 

  22. Head E, Phelan MJ, Doran E, et al. Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Commun. 2017;5(1):93.

    PubMed  PubMed Central  Google Scholar 

  23. Prasher VP, Farrer MJ, Kessling AM, et al. Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann Neurol. 1998;43:380–3.

    CAS  PubMed  Google Scholar 

  24. Doran E, Keator D, Head E, et al. Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: the role of APP. J Alzheimers Dis. 2017;56(2):459–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488(7409):96–9.

    CAS  PubMed  Google Scholar 

  26. Brier MR, Gordon B, Friedrichsen K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med. 2016;8(338):338ra66.

    PubMed  PubMed Central  Google Scholar 

  27. Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139(Pt 5):1551–67.

    PubMed  PubMed Central  Google Scholar 

  28. Margallo-Lana ML, Moore PB, Kay DW, et al. Fifteen-year follow-up of 92 hospitalized adults with Down’s syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J Intellect Disabil Res. 2007;51(Pt. 6):463–77.

    CAS  PubMed  Google Scholar 

  29. Beyreuther K, Masters CL. Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer’s disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol. 1991;1:241–51.

    CAS  PubMed  Google Scholar 

  30. Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–98.

    CAS  PubMed  Google Scholar 

  31. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5.

    CAS  PubMed  Google Scholar 

  32. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16(9):564–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Ball SL, Holland AJ, Hon J, et al. Personality and behaviour changes mark the early stages of Alzheimer’s disease in adults with Down’s syndrome: findings from a prospective population-based study. Int J Geriatr Psychiatry. 2006;21:661–73.

    PubMed  Google Scholar 

  35. Ball SL, Holland AJ, Treppner P, et al. Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer’s disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Cli. Psychol. 2008;47:1–29.

    Google Scholar 

  36. Dekker AD, Sacco S, Carfi A, et al. The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: comprehensive Assessment of Psychopathology in Down Syndrome. J Alzheimers Dis. 2018;63(2):797–819.

    PubMed  PubMed Central  Google Scholar 

  37. Lautarescu BA, Holland AJ, Zaman SH. The early presentation of dementia in people with Down syndrome: a systematic review of longitudinal studies. Neuropsychol Rev. 2017;27(1):31–45.

    PubMed  PubMed Central  Google Scholar 

  38. Dekker AD, Strydom A, Coppus AM, et al. Behavioural and psychological symptoms of dementia in Down syndrome: early indicators of clinical Alzheimer’s disease? Cortex. 2015;73:36–61.

    PubMed  Google Scholar 

  39. Holland AJ, Hon J, Huppert FA, et al. Incidence and course of dementia in people with Down’s syndrome: findings from a population-based study. J Intellect Disabil Res. 2000;44:138–46.

    PubMed  Google Scholar 

  40. Lott IT, Doran E, Nguyen VQ, et al. Down syndrome and dementia: seizures and cognitive decline. J Alzheimers Dis. 2012;29(1):177–85.

    PubMed  PubMed Central  Google Scholar 

  41. Menéndez M. Down syndrome, Alzheimer’s disease and seizures. Brain Dev. 2005;27(4):246–52.

    PubMed  Google Scholar 

  42. De Simone R, Puig XS, Gélisse P, et al. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer’s disease in Down syndrome. Seizure. 2010;19(7):383–9.

    PubMed  Google Scholar 

  43. Mann DM, Yates PO, Marcyniuk B. Alzheimer’s presenile dementia, senile dementia of Alzheimer type and Down’s syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984;10(3):185–207.

    CAS  PubMed  Google Scholar 

  44. Lemere CA, Blusztajn JK, Yamaguchi H, et al. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3:16–32.

    CAS  PubMed  Google Scholar 

  45. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150:296–304.

    CAS  PubMed  Google Scholar 

  46. Abrahamson EE, Head E, Lott IT, et al. Neuropathological correlates of amyloid PET imaging in Down syndrome. Dev Neurobiol. 2019;79(7):750–66.

    PubMed  Google Scholar 

  47. Cataldo AM, Peterhoff CM, Troncoso JC, et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157:277–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Thal DR, Rüb U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800.

    PubMed  Google Scholar 

  49. Davidson YS, Robinson A, Prasher VP, et al. The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome. Acta Neuropathol Commun. 2018;6(1):56.

    PubMed  PubMed Central  Google Scholar 

  50. Alonso AD, Grundke-Iqbal I, Iqbal K. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996;2:783–7.

    CAS  PubMed  Google Scholar 

  51. Alonso AC, Zaidi T, Novak M, et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA. 2001;98(12):6923–69238.

    CAS  PubMed  Google Scholar 

  52. Wilcock DM, Griffin WS. Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation. 2013;10:84.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Wilcock DM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer’s disease. Curr Gerontol Geriatr Res. 2012;2012:170276.

    PubMed  PubMed Central  Google Scholar 

  54. Wilcock DM, Hurban J, Helman AM, et al. Down syndrome individuals with Alzheimer’s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer’s disease. Neurobiol Aging. 2015;36(9):2468–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Landt J, D’Abrera JC, Holland AJ, et al. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Arch Neurol. 2011;68(7):890–6.

    PubMed  Google Scholar 

  56. Handen BL, Cohen AD, Channamalappa U, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 2012;8(6):496–501.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Rafii MS, Wishnek H, Brewer JB, et al. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome. Front Behav Neurosci. 2015;9:239.

    PubMed  PubMed Central  Google Scholar 

  58. Jennings D, Seibyl J, Sabbagh M, et al. Age dependence of brain β-amyloid deposition in Down syndrome: an [18F] florbetaben PET study. Neurology. 2015;84(5):500–7.

    CAS  PubMed  Google Scholar 

  59. Annus T, Wilson LR, Hong YT, et al. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2016;12(5):538–45.

    PubMed  PubMed Central  Google Scholar 

  60. Cole JH, Annus T, Wilson LR, et al. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Neurobiol Aging. 2017;56:41–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Lao PJ, Betthauser TJ, Hillmer AT, et al. The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement. 2016;12(4):380–90.

    PubMed  Google Scholar 

  62. Lao PJ, Handen BL, Betthauser TJ, et al. Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimers Dement (Amst). 2017;9:1–9.

    PubMed  PubMed Central  Google Scholar 

  63. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. Version 2. J Neurosci. 2007;27(23):6174–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66(12):1537–44.

    PubMed  Google Scholar 

  65. Cohen AD, McDade E, Christian B, et al. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer’s disease from late-onset amyloid deposition. Alzheimers Dement. 2018;14(6):743–50.

    PubMed  PubMed Central  Google Scholar 

  66. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.

    PubMed  PubMed Central  Google Scholar 

  67. Schöll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971–82.

    PubMed  PubMed Central  Google Scholar 

  68. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.

    PubMed  PubMed Central  Google Scholar 

  69. Rafii MS, Lukic AS, Andrews RD, et al. PET imaging of tau pathology and relationship to amyloid, longitudinal mri, and cognitive change in down syndrome: results from the down syndrome biomarker initiative (DSBI). J Alzheimers Dis. 2017;60(2):439–50.

    CAS  PubMed  Google Scholar 

  70. Forman MS, Zhukareva V, Bergeron C, et al. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol. 2002;160:2045–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Haier RJ, Head K, Head E, et al. Neuroimaging of individuals with Down’s syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage. 2008;39(3):1324–32.

    CAS  PubMed  Google Scholar 

  72. Matthews DC, Lukic AS, Andrews RD, et al. Dissociation of Down syndrome and Alzheimer’s disease effects with imaging. Alzheimers Dement (N Y). 2016;2(2):69–81.

    Google Scholar 

  73. Meltzer CC, Zubieta JK, Brandt J, et al. Regional hypometabolism in Alzheimer’s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology. 1996;47(2):454–61.

    CAS  PubMed  Google Scholar 

  74. Hof PR, Bouras C, Perl DP, et al. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional analysis and comparison with Alzheimer’s disease. Arch Neurol. 1995;52(4):379–91.

    CAS  PubMed  Google Scholar 

  75. Teipel SJ, Alexander GE, Schapiro MB, et al. Age-related cortical grey matter reductions in non-demented Down’s syndrome adults determined by MRI with voxel-based morphometry. Brain. 2004;127(Pt 4):811–24.

    PubMed  Google Scholar 

  76. Mullins D, Daly E, Simmons A, et al. Dementia in Down’s syndrome: an MRI comparison with Alzheimer’s disease in the general population. J Neurodev Disord. 2013;5(1):19.

    PubMed  PubMed Central  Google Scholar 

  77. Krasuski JS, Alexander GE, Horwitz B, et al. Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down’s syndrome: implications for the prodromal phase of Alzheimer’s disease. Am J Psychiatry. 2002;159(1):74–81.

    PubMed  Google Scholar 

  78. Beacher F, Daly E, Simmons A, et al. Alzheimer’s disease and Down’s syndrome: an in vivo MRI study. Psychol Med. 2009;39(4):675–84.

    CAS  PubMed  Google Scholar 

  79. Schupf N, Patel B, Pang D, et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64(7):1007–13.

    PubMed  PubMed Central  Google Scholar 

  80. Schupf N, Zigman WB, Tang MX, et al. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75(18):1639–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Dekker AD, Fortea J, Blesa R, et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease in Down syndrome. Alzheimers Dement (Amst). 2017;8:1–10.

    PubMed  PubMed Central  Google Scholar 

  82. Fortea J, Carmona-Iragui M, Benejam B, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17(10):860–9.

    CAS  PubMed  Google Scholar 

  83. Strydom A, Heslegrave A, Startin CM, et al. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimers Res Ther. 2018;10(1):39.

    PubMed  PubMed Central  Google Scholar 

  84. Rafii MS, Donohue MC, Matthews DC, et al. plasma neurofilament light and Alzheimer’s disease biomarkers in down syndrome: results from the down syndrome biomarker initiative (DSBI). J Alzheimers Dis. 2019;70(1):131–8.

    CAS  PubMed  Google Scholar 

  85. Mapstone M, Gross TJ, Macciardi F, et al. Metabolic correlates of prevalent mild cognitive impairment and Alzheimer’s disease in adults with Down syndrome. Alzheimers Dement (Amst). 2020;12(1):e12028.

    PubMed  PubMed Central  Google Scholar 

  86. Handen BL. The search for biomarkers of Alzheimer’s disease in down syndrome. Am J Intellect Dev Disabil. 2020;125(2):97–9.

    PubMed  Google Scholar 

  87. Esbensen AJ, Hooper SR, Fidler D, Outcome Measures Working Group, et al. Outcome Measures for Clinical Trials in Down Syndrome. Am J Intellect Dev Disabil. 2017;122(3):247–81.

    PubMed  PubMed Central  Google Scholar 

  88. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111–33.

    Google Scholar 

  89. Rafii MS, Aisen PS. Alzheimer’s disease clinical trials: moving toward successful prevention. CNS Drugs. 2019;33(2):99–106.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Strydom A, Coppus A, Blesa R, et al. Alzheimer’s disease in Down syndrome: an overlooked population for prevention trials. Alzheimers Dement (N Y). 2018;4:703–13.

    Google Scholar 

  91. Moran JA, Rafii MS, Keller SM, et al. The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin Proc. 2013;88(8):831–40.

    PubMed  Google Scholar 

  92. Walsh DM, Doran E, Silverman W, et al. Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status. J Intellect Disabil Res. 2015;59(11):1071–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Sheehan R, Sinai A, Bass N, et al. Dementia diagnostic criteria in Down syndrome. Int J Geriatr Psychiatry. 2015;30(8):857–63.

    PubMed  Google Scholar 

  94. Fenili D, Brown M, Rappaport R, et al. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med (Berl). 2007;85:603–11.

    CAS  Google Scholar 

  95. McLaurin J, Golomb R, Jurewicz A, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem. 2000;275:18495–502.

    CAS  PubMed  Google Scholar 

  96. Townsend M, Cleary JP, Mehta T, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006;60:668–76.

    CAS  PubMed  Google Scholar 

  97. Salloway S, Sperling R, Keren R, et al. ELND005-AD201 Investigators A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77:1253–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Rafii MS, Skotko BG, McDonough ME, et al. A randomized, double-blind, placebo-controlled, phase II study of oral ELND005 (scyllo-Inositol) in young adults with down syndrome without dementia. J Alzheimers Dis. 2017;58(2):401–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Muhs A, Hickman DT, Pihlgren M, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci USA. 2007;104(23):9810–5.

    CAS  PubMed  Google Scholar 

  100. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54.

    CAS  PubMed  Google Scholar 

  101. Lott IT, Head E. Dementia in down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15(3):135–47.

    PubMed  Google Scholar 

Download references

Acknowledgements

Michael S. Rafii has received funding support from NIH R61AG066543.

Author information

Authors and Affiliations

  1. Alzheimer’s Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, 9860 Mesa Rim Road, San Diego, CA, 92121, USA

    Michael S. Rafii

Authors
  1. Michael S. Rafii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael S. Rafii.

Ethics declarations

Funding

No funding sources were used to assist with the preparation of this manuscript.

Conflict of interest

Michael S. Rafii has served as consultant to AC Immune.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rafii, M.S. Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials. CNS Drugs 34, 785–794 (2020). https://doi.org/10.1007/s40263-020-00740-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-020-00740-6

Search

Navigation